Join
Live feed
·
PRReleasevia Quantisnow
Gain Therapeutics Inc. logo

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

ByQuantisnow·Wall Street's wire, on your screen.
GANX· Gain Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GANX (Gain Therapeutics Inc.) and more on Quantisnow.